Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $27.4 million.

  • Viking Therapeutics' Total Current Liabilities rose 1.49% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 1.49%. This contributed to the annual value of $27.4 million for FY2024, which is 43.26% up from last year.
  • According to the latest figures from FY2024, Viking Therapeutics' Total Current Liabilities is $27.4 million, which was up 43.26% from $19.1 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Total Current Liabilities registered a high of $27.4 million during FY2024, and its lowest value of $8.8 million during FY2021.
  • In the last 3 years, Viking Therapeutics' Total Current Liabilities had a median value of $21.9 million in 2022 and averaged $22.8 million.
  • In the last 5 years, Viking Therapeutics' Total Current Liabilities decreased by 27.63% in 2021 and then surged by 150.02% in 2022.
  • Viking Therapeutics' Total Current Liabilities (Yearly) stood at $12.1 million in 2020, then fell by 27.63% to $8.8 million in 2021, then skyrocketed by 150.02% to $21.9 million in 2022, then decreased by 12.81% to $19.1 million in 2023, then surged by 43.26% to $27.4 million in 2024.